Rivastigmine (transdermal patch)

Hextol (TN)

Ergotamine, dihydro, methanesulfonate (salt)

GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol

Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN)

Donepezil (transdermal patch, Alzheimer's disease)

2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487

Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate

Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine

E2006

PLX-3397

Colostrinin (TN)

Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680

Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)

Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest

Nirogacestat; 1290543-63-3; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01

Tau imaging agent)

(2,6-dichlorophenylacetyl)-guanidine; [(2,6-dichlorophenyl)acetyl]guanidine; [(2,6-Dichlorophenyl)acetyl]guanidine hydrochloride; 29110-47-2; 30OMY4G3MK; A902647; A918619; AB01563079_01; AKOS030255657; AKOS030526130; BCP09647; BDBM81984; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-; BPBio1_000415; BRD-K32830106-003-03-0; BRD-K32830106-003-11-3; BSPBio_000377; C02AC02; C07037; CAS_29110-47-2; CAS-29110-48-3; CCG-204609; CHEBI:5558; CHEMBL862; D08031; DB01018; DTXCID7026944; DTXSID9046944; EINECS 249-442-8; EN300-243924; Estulic; Estulic (Salt/Mix); Estulic (TN); FT-0669067; FT-0669068; GTPL522; Guanfacina; Guanfacina (INN-Spanish); Guanfacina [INN-Spanish]; GUANFACINE; Guanfacine (INN); Guanfacine [INN:BAN]; GUANFACINE [INN]; GUANFACINE [MI]; GUANFACINE [VANDF]; GUANFACINE [WHO-DD]; Guanfacine HCl; Guanfacine hydrochloride (Salt/Mix); Guanfacinum; Guanfacinum (INN-Latin); Guanfacinum [INN-Latin]; HY-17416A; J-017394; L000286; L013430; LON 798 (Salt/Mix); Lopac0_000519; Lopac-G-1043; MRF-0000019; N-(Diaminomethyliden)-2-(2,6-dichlorophenyl)acetamid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; N-amidino-2-(2,6-dichlorophenyl)acetamide; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; NCGC00015469-01; NCGC00015469-02; NCGC00015469-03; NCGC00015469-04; NCGC00015469-05; NCGC00015469-06; NCGC00015469-07; NCGC00024950-01; NCGC00024950-02; NCGC00024950-03; NSC 759121; NSC_3519; NSC-759121; Prestwick0_000339; Prestwick1_000339; Prestwick2_000339; Prestwick3_000339; Q5613599; RASPBERRYKETONEGLUCOSIDE; SCHEMBL35094; SDCCGSBI-0050502.P002; SPBio_002298; Tenex (Salt/Mix); Tocris-1030; UNII-30OMY4G3MK

951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide

LY3372993

(-)-methylbenzylamine; (+)-2-Methylbutylp-aminocinnamate; 103-67-3; 7KN7F4X49E; AI3-26793; AKOS000119094; AR1001; Benzenemethanamine, N-methyl-; benzyl methyl amine; benzyl methylamine; Benzyl(methyl)amine; BENZYLAMINE, N-METHYL; Benzylamine, N-methyl-; Benzylmethylamine; benzyl-methylamine; Benzyl-methyl-amine; Benzylmethyl-d3-amine; BRD-K44558320-003-01-7; CHEMBL1338; CS-W007426; DTXSID9048439; EC 203-133-4; EINECS 203-133-4; EN300-18191; F2190-0316; FT-0631560; HNMeBzl; HY-W007426; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H; KBio2_001842; KBio2_004410; KBio2_006978; KBioGR_002247; KBioSS_001842; M0164; methyl benzylamine; Methyl(phenylmethyl)amine; methyl-benzyl amine; Methylbenzylamine; Methylbenzylamine, N-; methylbezylamine; MFCD00008289; MLS004773900; N-(Phenylmethyl)methylamine; N-benzyl methyl amine; N-benzyl methylamine; N-benzylmethanamine; N-benzyl-methyl amine; N-Benzylmethylamine; N-benzyl-methylamine; N-Benzylmethylamine, 97%; N-Benzyl-N-methylamine; N-benzyl-N-methyl-amine; NCGC00166047-01; N-methyl benzyl amine; N-methyl benzylamine; N-methyl -benzylamine; N-Methyl(phenyl)methanamine; N-methyl-1-phenylmethanamine; N-methyl-1-phenyl-methanamine; N-methylbenzenemethanamine; N-methyl-benzenemethanamine; N-methylbenzyl amine; N-methyl-benzyl amine; N-METHYLBENZYLAMINE; N-methyl-benzylamine; N-methyl-N-(phenylmethyl)amine; N-methyl-N-benzyl amine; N-methyl-N-benzylamine; N-Methy-N-benzylamine; NSC 8059; NSC8059; NSC-8059; omega-Methylaminotoluene; Q23978278; Racemic methylbenzyl amine; SCHEMBL2271; SDCCGMLS-0066901.P001; SMR000112361; Spectrum_001362; Spectrum4_001764; Spectrum5_000347; STR02536; UNII-7KN7F4X49E; W-108843; Z57327124

sodium oligomannate

BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec

isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA

1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane

NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics

GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline

MABT5102A; RG7412

example 25 (US8940748)

RG1450

PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer

NUC-1031

7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930

AC1L9R2T; 6-[3-acetamido-2-[6-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

Encenicline; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626

ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen

TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen

AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan

TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075

Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS

Beta secretase inhibitor (Alzheimer's disease), Eisai

CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate

Nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino

Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company

Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx

WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn

Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine

Tamibarotene (oral, Alzheimer's disease)

(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid ethyl ester; (5Z,8Z,11Z,14Z,17Z)-Eicosapetaenoic acid ethyl ester; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; 5,8,11,14,17-eicosapentaenoic acid, ethyl ester, (5Z,8Z,11Z,14Z,17Z)-; 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; 5-8-11-14-17-all cis-eicosapentaenoic acid ethyl ester; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid, ethyl ester; 6GC8A4PAYH; 73310-10-8; 86227-47-6; 86227-47-6 for all ''Z'' compound, 73310-10-8 for ''undefined'' compound; AB01563352_01; AC-33765; AKOS025295847; all cis-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester; all-cis-ethyl 5,8,11,14,17-icosapentaenoate; AMR 101; AMR101; AMR-101; BS-48985; CCG-213714; CHEBI:80366; CHEBI:84883; CHEMBL2095209; cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester; cis-5,8,11,14,17-Eicosapentaenoic acidethyl ester; cis-Eicosapentaenoic acid ethyl ester; CS-5304; D01892; DB08887; DTXSID601018686; E0442; E0853; E-EPA; Eicosapentaenoic acid (ethyl ester); Eicosapentaenoic acid ethyl ester; EICOSAPENTAENOIC ACID ETHYL ESTER (MART.); EICOSAPENTAENOIC ACID ETHYL ESTER (USP-RS); EICOSAPENTAENOIC ACID ETHYL ESTER [MART.]; EICOSAPENTAENOIC ACID ETHYL ESTER [MI]; EICOSAPENTAENOIC ACID ETHYL ESTER [USP-RS]; EICOSAPENTAENOIC ACID ETHYL ESTER [WHO-DD]; Eicosapentaenoic acid, ethyl ester; Eicosapentaenoicacidethylester; EICOSAPENTAENOICACIDETHYLESTER(EPAEE)(SG); EN300-25951782; EPA ethyl ester; Epadel; Epadel S; Epadel S (TN); EPA-E; Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate; ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate; Ethyl (all cis)-5,8,11,14,17-icosapentaenoate; Ethyl all cis-5,8,11,14,17-Eicosapentaenoate; Ethyl all cis-5,8,11,14,17-Icosapentaenoate; ethyl all-cis-5,8,11,14,17-icosapentaenoate; Ethyl all-cis-5,8,11,14,17-icosapentaenoic acid; ethyl eicosapentaenoate; Ethyl eicosapentaenoic acid; Ethyl EPA; Ethyl ester(all-Z)-5,8,11,14,17-Eicosapentaenoic acid; Ethyl icosapent; ethyl icosapentaenoate; ethyl icosapentate; Ethyl icosapentate (JP17); Ethyl icosapentate [JAN]; Ethyl icosapentate, JAN; ethyl-eicosapentaenoic acid; ethyl-EPA; GTPL7441; HMS2094K19; HY-B0747; ICOSAPENT ETHYL; Icosapent ethyl (USAN); ICOSAPENT ETHYL [ORANGE BOOK]; Icosapent ethyl [USAN]; ICOSAPENT ETHYL [VANDF]; Icosapent ethyl ester; LMFA07010877; MFCD00673476; MND 21; NSC 759597; NSC759597; NSC-759597; Pharmakon1600-01300030; Q5404453; s6466; SBI-0206684.P002; SCHEMBL123305; SR-05000002595; SR-05000002595-1; Timnodonic acid ethyl ester; UNII-6GC8A4PAYH; Vascepa; Vascepa (TN); Vazkepa

2093305-05-4; AKOS040757261; ATH-1017; ATH-1017 FREE ACID; CHEMBL5095419; CS-0204081; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate; Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN:INN]; Fosgonimeton [USAN]; H91OA9858J; HY-132814; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; NDX-1017; NDX-1017 FREE ACID; UNII-H91OA9858J; WHO 11782

2211981-76-7; Atuzaginstat; Atuzaginstat [INN]; AtuzaginstatCOR388; BDBM453275; CHEMBL5095230; COR388; COR-388; Cyclopentanecarboxamide, N-((1S)-5-amino-1-(2-(2,3,6-trifluorophenoxy)acetyl)pentyl)-; DGN7ROZ8EN; EX-A6081; N-((3S)-7-Amino-2-oxo-1-(2,3,6- trifluorophenoxy)heptan-3-yl)cyclopentanecarboxamide; N-[(3S)-7-amino-2-oxo-1-(2,3,6-trifluorophenoxy)heptan-3-yl]cyclopentanecarboxamide; SCHEMBL19972758; UNII-DGN7ROZ8EN; US10730826, Compound 1a-non-racemic; US10730826, Compound 1a-racemic

Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis

CNP520

Modified Hyaluronate

CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099

NeuroAiD

2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; CS-0433932; EX-A6549; GLXC-25705; GTPL11953; HY-144681; LY3372689; LY-3372689; MS-26295; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide; SCHEMBL20421995; U0SGP6ZX2V; UNII-U0SGP6ZX2V

2201048-82-8; 8-(2-Fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo(1,2-a)pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]imidazo[1,2-a]pyrazine; AKOS040757400; CS-0376702; CY6463; CY-6463; EX-A7620; GTKNNCQKFKGSHR-UHFFFAOYSA-N; H7KEN3O8AI; HY-145607; Imidazo(1,2-a)pyrazine, 8-((2-fluorophenyl)methyl)-6-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-; Imidazo[1,2-a]pyrazine, 8-[(2-fluorophenyl)methyl]-6-[5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl]-; IW-6463; MS-25746; SCHEMBL19922804; UNII-H7KEN3O8AI; Zagociguat; Zagociguat [INN]; ZAGOCIGUAT [USAN]

(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb onylthio)pent-3-enyl dihydrogen phosphate; (Z)-S-(2-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) benzothioate; {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl]oxy}phosphonic acid; 22457-89-2; 22457-89-2 (free acid); 775256-41-2; AC-8280; AKOS015920320; Benfotamine; Benfotiamina; benfotiamine; Benfotiamine (JAN/INN); Benfotiaminum; Benphothiamine; Benzoylthiamine monophosphate; Betivina; Biotamin (TN); BPBio1_000757; BSPBio_000687; CAS-22457-89-2; CCG-220654; CHEBI:41039; CHEMBL4303665; D01255; DB11748; DTXCID1025433; DTXSID3045433; EN300-21694383; HMS1570C09; HMS2097C09; HMS3714C09; MFCD00057343; N-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate; NCGC00016764-01; NCGC00016764-04; NCGC00179477-01; Prestwick_68; Prestwick2_000654; Prestwick3_000654; S-(2-(N-((4-Amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl)benzothioa; S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate; s-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] benzenecarbothioate; s-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate; S-{(1Z)-2-[[(4-Amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} benzenecarbothioate, AldrichCPR; S-Benzoylthiamine monophosphate; S-Benzoylthiamine O-monophosphate; S-Benzoylthiamine-O-monophosphate; SCHEMBL188070; SCHEMBL19184708; SR-01000872627; SR-01000872627-1; SR-01000872627-2; Tox21_110597; Tox21_110597_1

(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N

RG6416

Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate

(1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate; (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E, 4E)-2,4-octadienoic acid ester; [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate; 2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-; 2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,4E),13E,15R*,17S*(S*),21S*,23S*,25R*))-; 37O2X55Y9E; 83314-01-6; BDBM50258529; BMY-45618; BRN 4349157; BRYOSTATIN; Bryostatin 1; Bryostatin 1 - CAS 83314-01-6; BRYOSTATIN 1 [MI]; BRYOSTATIN 1 [WHO-DD]; Bryostatin 1, >=99%, solid; Bryostatin-1; CHEBI:88353; CHEMBL449158; CS-0025440; DTXSID8046876; HY-105231; MFCD00893832; MJQUEDHRCUIRLF-TVIXENOKSA-N; NSC 339555; NSC-339555; Q27095907; SCHEMBL182960; UNII-37O2X55Y9E

RO7105705

UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6

1531586-58-9; 6'-(2-(1-(Pyridin-2-ylmethyl)piperidin-4-yl)ethyl)spiro[cyClopropane-1,5'-[1,3]dioxolo[4,5-f]isoindol]-7'(6'H)-one; AD-35; BDBM231544; CHEMBL3949886; GLXC-15057; IND-120499; SCHEMBL15598869; starbld0021420; US9346818, I-29; US9346818, I-33; US9346818, I-35

(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N

RG6102

849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546

1628502-91-9; 3GF; 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methyl-piperazin-1-yl)-(2-naphthalen-2-yl)-4-pyridin-4-ylpyridazine; 6-(4-Methylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)pyridazine; 6-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine; AKOS040758765; BDBM50537600; CHEMBL4129018; CIIVUDIZZJLXCN-UHFFFAOYSA-N; compound 11 [PMID: 30978288]; compound 27 [WO2014145485A2]; compound 8 [PMID: 25676389]; CS-0069509; EPZ68T461K; EX-A3206A; GTPL10524; HY-120111; MS-26255; MW 150; MW01-18-150SRM; MW150; MW-150; NSC785340; NSC-785340; Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-; Q27453797; SCHEMBL16061104; UNII-EPZ68T461K

SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven

S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier

Betabloc; AIP-001

Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)

D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336

PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer

IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD

Posiphen (TN)

FK-960 analog, Fujisawa

SAR-110894D

UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4

Anti-obesity hormone-based therapy, Manhattan

Motiva (TN)

KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide

C2N-8E12

669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane

CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex

SAM-760

Elayta

1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475

BAC; D-Bacillosamine; Bacillosamine; D-Bac; 2,4-Diamino-2,4,6-Trideoxy-D-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucose; 2,4-Diamino-2,4,6-Trideoxy-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucose; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranose; 2,4-Diamino-2,4,6-Trideoxy-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-Glucopyranoside; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranose; 2,4,6-Trideoxy-2,4-Diamino-D-Glucopyranoside; 2,4-Diamino-2,4,6-Trideoxy-D-Gluc

Edonerpic maleate; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:

Bryostatin 1; 83314-01-6

M-IQ 001; Fatty acid metabolism inhibitor (Alzheimer's disease), Meta-IQ

1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha

Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326

NDD-094A; SDZ-NDD-094

Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219

Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion

BCP16255

720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K

FDTAUJJRHBRHIJ-BBGIBMRQSA-N; 849213-15-6; SCHEMBL19374618; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-, (1S,2S,4S,7S,7aR,10aS,11aR,13aS,13bR,13cS)-7,13a-bis(acetyloxy)-1-(benzoyloxy)-9-ethenyl-1,3,4,7,7a,10a,11,11a,13,13a,13b,13c-dodecahydro-2-hydroxy-5,13c,14,14-tetramethyl-2,6-methano-2H-cyclodec(de)oxeto(3,2-g)(1,3)benzodioxin-4-yl ester, (2R,3S)-

ST 101 [French]; 7-Chloro-1,3-dihydro-5-phenyl-1-trimethylgermyl-2H-1,4-benzodiazepin-2-one; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2 [French]; 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-5-phenyl-1-trimethylgermyl-; AC1O4GHW; ST 101; LS-34275; Trimethyl germyl-1, chloro-7, dihydro-1-3, phenyl-5 2H benzodiazepine-1-4 one-2

UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide

Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite

CHF 5074; CHF5074; 749269-83-8; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261

M1 receptor modulator; 1227923-29-6; MK7622; MK 7622; 3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one; SCHEMBL2399084; EX-A804; JUVQLZBJFOGEEO-GOTSBHOMSA-N; BCP27739; ZINC95930184; AKOS028113668; DB12897; CS-5442; HY-15618; Benzo(H)quinazolin-4(3H)-one, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methyl-3-pyridinyl)methyl)-; AS-35236; KB-145903; J-690076; UNII-57R7D1Q49R component JUVQLZBJFOGEEO-GOTSBHOMSA-N

5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)

Avagacestat

T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens

471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635

Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid

Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming

LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly

BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells

TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca

UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate

ACC-001

MSDC-0160; Mitoglitazone (TN)

AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana

Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819

Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215

(5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone; 1346013-80-6; compound 4 [PMID: 28012176]; GLXC-26582; GTPL12037; SCHEMBL23207782; SCHEMBL23798797; starbld0030988; UE2343; UE-2343; Xanamem

N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide

AAVrh.10hAPOE2

ACI-35

Latozinemab

Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals

Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune

VLP norovirus bivalent vaccine (intranasal, norovirus-induced gastroenteritis)

MK 2461

1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione

(2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone; (2,4-Dimethylpyridin-3-yl)(4-methyl-4-((S)-3-methyl-4-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{(S)-3-methyl-4-[(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-Dimethyl-pyridin-3-yl)-(4-methyl-4-{3-methyl-4-[1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone; (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3S)-3-methyl-4-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone; 306293-36-7; AD101; BDBM50104946; CHEMBL113436; DTKUANPECHGGBY-UNMCSNQZSA-N; PD084304; Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2S)-; SCHEMBL4453513

1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475

(E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; 1146963-51-0; 1807913-16-1; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; A894156; AC-35232; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; AKOS024458485; AS-16718; CCG-268030; CHEBI:192601; CHEMBL2387144; CS-3688; DB13957; DTXSID501045787; EX-A2235; HMS3886O17; HY-13779; HYMZAYGFKNNHDN-SSDVNMTOSA-N; j147; J-147; MFCD25976644; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; s5269; SCHEMBL12995834; SCHEMBL21294999; UNII-Z41H3C5BT9; Z41H3C5BT9

TAK-920

MDA7

(4R,5R)-5-(2-Chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one; 1375752-78-5; 2-Oxazolidinone, 5-(2-chlorophenyl)-4-(5-(2-phenylethynyl)-3-pyridinyl)-, (4R,5R)-; 3I1803DK5Z; AKOS040756698; BDBM50536712; BMS984923; BMS-984923; CHEMBL4571075; CS-0087012; HY-122559; SCHEMBL4541143; UNII-3I1803DK5Z

Carbon-11-6-Me-BTA-1; 11C-BTA-1

ZLZUHACSRMOLLV-RAALSFIWSA-N; 1818339-66-0; UNII-1Y0Y126GUG; 1Y0Y126GUG; US9315520, Example 1; CHEMBL3952064; US9315520, Example 2; US9315520, Comparator 1; SCHEMBL17162186; BDBM223395; HY-112157; CS-0043501; US9315520, 1; N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide; N-{2-[(4aR,6S,8aR)-2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl]-1,3-thiazol-4-yl}-5-(difluoromethoxy)pyridine-2-carb

AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS

AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184

WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth

ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer

LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,

Exebryl-1 (TN)

Diagnostic PET imaging agent (Alzheimer's disease), Bayer

Alzheimer's diagnostic, IND; 123I-SPECT diagnostic (Alzheimer's disease), IND

LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,

DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole

PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth

Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech

Bisnormcerysine

870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N

WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine

GSK-2647544

ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene

GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953

UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073

DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride

WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5

SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals

DWJ-301

P-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma

RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene

NCAM mimetics (Alzheimer's disease), Enkam

CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion

GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D

UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, > 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol

927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID

Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics

MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate

17-phenyl-omega-trinor-PGF2alpha

1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, > Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide

GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide

PMID29324067-Compound-53

PMID28270010-Compound-Figure18-1

PMID29324067-Compound-43

TAK-147

Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261

AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]

S 18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine

CP-457,920

MLV-6976; NC-1200; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one

RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine

Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398

Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane

Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals

191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride

Inflammation therapeutics, Vasogen; VP-015

MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche

AAB-003

Neuroregeneration enhancer (oral, Alzheimers/Parkinsons disease), Takeda

Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira

71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate

AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals

Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359

Heat shock protein 70 inhibitor (cancer), Vernalis; Hsp 70 inhibitor (cancer), Vernalis

DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech

SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough

formyl humanin

Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M

IDRA-21 analogs; IDRA-5

Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-

ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-

EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit

PD-142676

BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one

BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo

MDL-2170

7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ

102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2

Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia

Nicotinic ACh agonists, Novo Nordisk

Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre

SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune

Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S

CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294

MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet

119737-52-9; Butanoic acid, 4-(((3-methyl-5-isoxazolyl)carbonyl)amino)-; Butanoic acid,4-[[(3-methyl-5-isoxazolyl)carbonyl]amino]-; ACMC-20cew8; AC1Q5P7F; SCHEMBL195378; AC1L4P39; CTK4B1474; 4-[(3-methyl-1,2-oxazole-5-carbonyl)amino]butanoic acid; DTXSID50152568; 4-{[(3-methyl-1,2-oxazol-5-yl)carbonyl]amino}butanoic acid

RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-

RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl -D-galactopyranoside; 2-Nitrophenyl; A-D-galactopyranoside

FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-

AZD2858; 486424-20-8; AZD 2858; CHEMBL2177161; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide; 3-Amino-6-{4-[(4-Methylpiperazin-1-Yl)sulfonyl]phenyl}-N-Pyridin-3-Ylpyrazine-2-Carboxamide; GSK-3 inhibition; 3-amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL8478; SCHEMBL3327702; C21H23N7O3S; EX-A707; AOB6850; MolPort-035-395-808